ESTRO 2024 - Abstract Book

S98 ESTRO 2024 escalated will be explored, encompassing considerations such as overall dose versus dose to specific organs at risk (OARs), the potential advantages of proton therapy, the role of MR-guided radiation therapy, and strategies for lowering the dose to involved mediastinal nodes. I will also discuss the future landscape, suggesting that further intensification of radiation doses might not be the solution. Instead, I will advocate a multi-modality treatment approach, involving the integration of systemic anticancer therapies, particularly immunotherapy, with radiation treatment. The need to personalize radiation treatments will be highlighted, emphasizing the role of circulating tumor DNA (ctDNA) in making informed decisions about consolidation immunotherapy. This presentation aims to shed light on the need to shift towards dose de-escalation in the management of stage 3 NSCLC. It will emphasise the importance of tailored and multimodality treatment strategies to enhance efficacy while mitigating treatment-related toxicities. Invited Speaker

3488

Recent advances in dermatooncology – ESTRO view

Agata Rembielak

The Christie Hospital, Clinical Oncology, Manchester, United Kingdom. The University of Manchester, Division of Cancer Studies, Manchester, United Kingdom

Abstract:

The worldwide incidence of skin cancer continues to increase as the global population ages. Non-melanoma skin cancer (NMSC) represents the most frequently diagnosed malignancy worldwide, most being basal cell and cutaneous squamous cell carcinoma. Numerous treatment options are available for patients with NMSC. Majority of low risk and early stage NMSCs can be successfully cured with medical/ medicophysical or surgical treatments. Radiotherapy is an excellent alternative where surgery is not a viable option (medically/technically inoperable) or considered less ideal (e.g. concerns regarding cosmetic or functional impairment). Frail and elderly patients with poor performance status can benefit from short-course hypofractionated radiotherapy, with very acceptable toxicity. Adjuvant radiotherapy in patients with unfavourable pathology can decrease the risk of local and regional recurrence and associated morbidity and mortality. Palliative radiotherapy can be an excellent option in symptom control in the absence of viable radical treatments. Advanced NMSC requires multispecialty involvement within Multidisciplinary Tumour Board. Recent advancements in systemic treatments in skin cancer include immunotherapy and targeted therapies. This session highlights the need for interdisciplinary cooperation between dermatologists, dermato-oncologist, surgeons, radiation oncologist, onco-geriatrician and allied health care professionals involved in the management of skin cancer. The recently signed Memorandum of Understanding between ESTRO and EADO leads the example of such continued mutual understanding of advancements in each specialty allowing to work together towards a common goal. The talk will focus on the most recent advances in skin oncology with particular emphasis on skin radiotherapy and brachytherapy and on currently ongoing clinical trials in the field of NMSC.

3489

Re-irradiation: Radiotherapy in previously irradiated rectal cancer